Andy Stergachis
Professor of Pharmacy, Global Health & Adjunct Professor of Epidemiology and Health Services
Center for Pharmacy Practice Transformation, CHOICE Faculty, Department of Pharmacy, Pharmacy Faculty, School Faculty
Telephone: (206) 221-0703
Email: stergach@uw.edu
Office Location: SCC 248A. Box 357631 1959 NE Pacific St Seattle, WA 98195
Website: Global Medicines Program
Expertise:
Education
- PhD in Social & Administrative Pharmacy, University of Minnesota
- MS in Pharmacy Administration, University of Minnesota
- BPharm Pharmacy, Washington State University
Courses Taught
- Pharm 581/GH 543: Global Health Pharmacy
Biography
Andy Stergachis is Professor of Pharmacy and Global Health and Adjunct Professor of Health Services and Epidemiology, and Director of the Global Medicines Program, University of Washington. He is an author of 237 peer-reviewed publications in areas such as drug safety, pharmaceutical outcomes, and clinical epidemiology. A licensed pharmacist, he served as Editor-in-Chief of the Journal of the American Pharmacists Association for 6 years until 2019. He is a member of the CEPI Maternal Immunization Working Group; Chair of the Scientific Advisory Board for the Pregnancy Registry to Assess the Safety of Antimalarial use in Pregnancy, and Member, Executive Board, Safety Platform for Emergency Vaccines (SPEAC), Brighton Collaboration, The Task Force for Global Health. He is an elected member of the National Academy of Medicine, and Fellow of the International Society for Pharmacoepidemiology, American Pharmacists Association, American Association for the Advancement of Science, Washington State Pharmacy Association, and the Washington State Academy of Science. Since 2010, He has chaired multiple student doctoral dissertation committees, mentored postdoctoral trainees, served as member of numerous graduate student PhD dissertation and MPH thesis committees, and served as advisor to multiple graduate students.
His research has made major contributions to advancing the safety of medications and vaccines. He has developed and evaluated novel approaches for safety surveillance of vaccines and essential medicines, including medicines for HIV/AIDS, as well as for the evaluating innovative pharmacy-based services in low- and middle-income countries. His recent projects include pharmacovigilance system strengthening; active safety surveillance of TB preventive therapy for PLHIV; sentinel site readiness for maternal immunization active safety surveillance; global burden of antimicrobial resistance; and evaluating and optimizing a virtual care model for PrEP delivery. He is currently PI of the University of Washington component of the Background Incidence Rates in Africa project funded by the Gates Foundation and co-investigator with several other global medicines projects, including with the Institute for Health Metrics and Evaluation on the global burden of antimicrobial resistance. Through his affiliation with the Northwest Center for Public Health Practice, he also works on workforce development and research in emergency preparedness with the public health community.
Selected Publications
- Wittenauer R, Bacci J, Shah P, Stergachis A. Vaccination payments in states with provider status: a claims analysis. J Am Pharm Assoc (2003). 2025 Jan-Feb;65(1):102301. doi: 10.1016/j.japh.2024.102301. Epub 2024 Nov 23 1
- Munoz FM, Kampmann B, Stergachis A, Chaudhary M, Cutland CL, Khalil A, Gentile A, Jones CE, Marshall H, Sevene E, Darko DM, Swamy G, Hyde TB, Voss G, Muelen AS. A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women. Vaccine. 2025 Jul 18;62:127513.
- Bardach A, Brizuela M, Berrueta M, Ciapponi A, Sambade JM, Ballivian J, Ortega V, Castellana N, Comandé D, Parker EPK, Kampmann B, Stegelmann K, Xiong X, Stergachis A, Munoz FM, Buekens P, Mazzoni A. Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines. Hum Vaccin Immunother. 2025 Dec;21(1):2463191.
- GBD 2021 Global Stillbirths Collaborators. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021. Lancet. 2024 Nov 16;404(10466):1955-1988. (co-author).
- GBD 2023 Vaccine Coverage Collaborators. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037-2 (co-author)
- Chaudhary M, Cutland CL, Bonet M, Gentile A, Jones CE, Marshall HS, Stergachis A, Voss G, Darko DM, Sevene E, Hyde T, Fairlie L, Kampmann B, Everett D, Munoz FM. Burden of Lassa fever disease in pregnant women and children and options for prevention. Vaccine. 2024 Nov 1;43:126479.
- Ciapponi A, Berrueta M, Argento FJ, Ballivian J, Bardach A, Brizuela ME, Castellana N, Comandé D, Gottlieb S, Kampmann B, Mazzoni A, Parker EPK, Sambade JM, Stegelmann K, Xiong X, Stergachis A, Buekens P. Safety and Effectiveness of COVID-19 Vaccines during Pregnancy: A Living Systematic Review and Meta-Analysis. Drug Safety. Drug Saf. 2024 Jul 15.
- Montaño MA, Chen Y, Saldarriaga EM, Thuo N, Kiptinness C, Stergachis A, Mugambi ML, Ngure K, Ortblad KF, Sharma M. Willingness to pay for HIV pre- and post-exposure prophylaxis services delivered via an online pharmacy in Kenya. BMC Health Serv Res. 2025 Apr 22;25(1):576. doi: 10.1186/s12913-025-12766-x. PMID: 40264148.
- Chen Y, Montaño MA, Naik P, Thuo N, Kiptinness C, Rafferty M, Stergachis A, Mugambi ML, Ngure K, Ortblad KF, Sharma M. Incremental cost of pre- and post-exposure prophylaxis service provision via an online pharmacy in Kenya. J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003680. Epub ahead of print. PMID: 40198924.
- Sahu M, Wagner TD, Thomson A, Beauchamp M, Campbell JD, Crosby S, DeJarnatt D, Lescinsky H, Salih RK, Taylor K, Weil M, Dwyer-Lindgren L, Haakenstad A, Scott JW, Stergachis A, Essien UR, Dieleman JL. Variation in Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, Health Condition, and US State. JAMA Health Forum. 2025 Aug 1;6(8):e252329.